Pembrolizumab-vibostolimab with etoposide and platinum chemotherapy is in clinical development for the first-line treatment of extensive stage small cell lung cancer (SCLC). Extensive stage SCLC is when cancer cells form in the tissues of the lung and spread beyond the lung to other places in the body. Symptoms include chest pain, a cough that does not go away or gets worse, coughing up blood, and breathlessness. Smoking is the biggest risk factor for SCLC. Extensive-stage SCLC is a challenging disease to treat and despite improvements in the treatment of the disease, most patients will have disease progression within 6 months.
Pembrolizumab-vibostolimab with etoposide and platinum chemotherapy for previously untreated extensive-stage small cell lung cancer
Pembrolizumab-vibostolimab with etoposide and platinum chemotherapy is in clinical development for the first-line treatment of extensive stage small cell lung cancer (SCLC). Extensive stage SCLC is when cancer cells form in the tissues of the lung and spread beyond the lung to other places in the body.
Interventions:
Etoposide
, Pembrolizumab-vibostolimab (MK-7684; MK7684A; Vibostolimab)
, Platinum-based chemotherapy
Indications:
Small-cell lung cancer (SCLC)
Therapeutic Areas:
Lung and Respiratory Cancer
Year:
2023